Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Cancer Demo May Encourage Use Of EPO, Anti-Emetics

This article was originally published in The Pink Sheet Daily

Executive Summary

The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005

You may also be interested in...



Reduced Cancer Drug Reimbursements Don’t Impede Access – JAMA Study

2003-2006 Medicare claim review finds no evidence that lowering physician payments adversely affected access to care.

Reduced Cancer Drug Reimbursements Don’t Impede Access – JAMA Study

2003-2006 Medicare claim review finds no evidence that lowering physician payments adversely affected access to care.

CMS Cancer "Quality Of Care" Data Show "A Lot Of Variations," McClellan Says

Preliminary data from the oncology demonstration project show variable quality-of-life outcomes, likely because many patients have late-stage cancer, CMS Administrator McClellan says. The program may ultimately help drive improvements in clinical practices, he predicts.

Related Content

Topics

UsernamePublicRestriction

Register

PS058081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel